Monitoring Agency Report for Quarter Ended September 30, 2025
Camlin Fine Sciences submits Monitoring Agency Report for quarter ended September 30, 2025, confirming no deviation in utilization of funds raised through Rights Issue.
The announcement is a compliance report and does not have a significant impact on the company's operations or financials.
The announcement is a routine compliance report with no indication of positive or negative impact.
* Camlin Fine Sciences Limited has submitted the Monitoring Agency Report for the quarter ended September 30, 2025, regarding the utilization of funds raised through the Rights Issue of Equity Shares. * The report was reviewed and approved by the Audit Committee and the Board of Directors on November 10, 2025. * The monitoring agency is India Ratings & Research Private Limited. * There has been no deviation in the utilization of issue proceeds from the objects stated in the Letter of Offer for the Rights Issue. * The rights issue involved 2,04,26,244 Equity Shares of ₹ 1 each at ₹ 110 per Equity Share, with an issue size of ₹ 22,468.87 lakhs. * The funds were primarily used for prepayment/repayment of borrowings (₹ 16,904.93 lakhs) and general corporate purposes (₹ 5,494.22 lakhs). * A portion of the funds is deployed in fixed deposits with State Bank of India.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under rights issue. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.